Modeling-error robustness of a viral-load preconditioning strategy for HIV treatment switching

In previous work, we have developed optimal-control based approaches that seek to minimize the risk of subsequent virological failure by “pre-conditioning” the viral load during therapy switches. In this paper, we use Monte-Carlo methods to evaluate the sensitivity of an open-loop implementation of these approaches to modeling errors. To account for hidden parameter dependencies, we use parameter distributions obtained from the convergence of Bayesian parameter estimation techniques applied to sets of clinical data obtained during serial therapy interruptions as the distribution from which the Monte-Carlo method samples.

[1]  R. Zurakowski,et al.  A new strategy to decrease risk of resistance emerging during therapy switching in HIV treatment , 2008, 2008 American Control Conference.

[2]  M. Wainberg,et al.  Antiretroviral Therapy , 2008, Drugs.

[3]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Michael S Saag,et al.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.

[5]  R. Paredes,et al.  Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression , 2000, AIDS.

[6]  S Bonhoeffer,et al.  Production of resistant HIV mutants during antiretroviral therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Nowak,et al.  Pre–existence and emergence of drug resistance in HIV–1 infection , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[8]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[9]  Martin S. Hirsch,et al.  Treatment for adult HIV infection. , 2004 .

[10]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[11]  Haihong Zhu,et al.  Parameter Identifiability and Estimation of HIV/AIDS Dynamic Models , 2008, Bulletin of mathematical biology.

[12]  X. Xia ESTIMATION OF HIV/AIDS PARAMETERS , 2002 .

[13]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[14]  S. Orsega,et al.  Treatment of Adult HIV Infection: Antiretroviral Update and Overview , 2007 .

[15]  Michael J. Piovoso,et al.  A generalized multi-strain model of HIV evolution with implications for drug-resistance management , 2009, 2009 American Control Conference.

[16]  Hulin Wu,et al.  Hierarchical Bayesian Methods for Estimation of Parameters in a Longitudinal HIV Dynamic System , 2006, Biometrics.

[17]  John Bartlett,et al.  Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States , 2004 .

[18]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[19]  Dominik Wodarz,et al.  Treatment interruptions to decrease risk of resistance emerging during therapy switching in HIV treatment , 2007, 2007 46th IEEE Conference on Decision and Control.

[20]  Michael S Saag,et al.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[21]  Victoria A Johnson,et al.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  R. Paredes,et al.  HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection , 2001, AIDS.

[23]  A. Telenti,et al.  HIV treatment failure: testing for HIV resistance in clinical practice. , 1998, Science.

[24]  Somnuek Sungkanuparph,et al.  Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. , 2008, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[25]  Ryan Zurakowski,et al.  Resistance Risk Management in HIV Therapy Switching with Explicit Quiescent T-Cell Modeling , 2008 .

[26]  D L Barnard,et al.  A new form of antiviral combination therapy predicted to prevent resistance from arising, and a model system to test it. , 2001, Current medicinal chemistry.